TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients.
TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy-induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
2010
Size (employees)
446 (est)
TESARO was founded in 2010 and is headquartered in Waltham, US

TESARO Office Locations

TESARO has an office in Waltham
Waltham, US (HQ)
3300 1000 Winter St

TESARO Data and Metrics

TESARO Financial Metrics

TESARO's revenue was reported to be $3.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

3.1 m

Net income (Q1, 2017)

(136.7 m)

EBIT (Q1, 2017)

(133.2 m)

Market capitalization (21-Jul-2017)

7.2 b

Cash (31-Mar-2017)

672.2 m
TESARO's current market capitalization is $7.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

317 k44.8 m

Revenue growth, %

14040%

R&D expense

235.1 m

General and administrative expense

158.6 m

Operating expense total

92.4 m167.3 m236.4 m415.8 m

EBIT

(92.4 m)(167.3 m)(236 m)(371 m)

EBIT margin, %

(74461%)(828%)

Interest expense

3.8 m15.4 m16.5 m

Interest income

83 k24 k48 k1.4 m

Income tax expense

1.5 m

Net Income

(92.4 m)(171 m)(251.4 m)(387.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

307 k36.6 m3.7 m3.1 m

R&D expense

30.6 m29.9 m33.5 m38.9 m40.1 m52.6 m50.1 m60.8 m66.1 m

General and administrative expense

5.6 m6.3 m11.2 m16.8 m22.8 m30 m36.2 m37.7 m69.3 m

Operating expense total

36.2 m36.2 m44.8 m55.7 m62.8 m82.7 m86.4 m98.5 m135.4 m

EBIT

(37.1 m)(36.2 m)(44.8 m)(56.7 m)(62.7 m)(86.9 m)(54.5 m)(97.6 m)(133.2 m)

EBIT margin, %

(28302%)(149%)(2616%)(4336%)

Interest expense

42 k(3.7 m)(3.9 m)(3.9 m)(4 m)(4.1 m)(4.1 m)(4.3 m)

Interest income

5 k4 k7 k9 k9 k102 k209 k532 k841 k

Pre tax profit

(136.7 m)

Income tax expense

54 k

Net Income

(37.1 m)(36.2 m)(48.5 m)(60.6 m)(66.6 m)(90.8 m)(58.4 m)(101.2 m)(136.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

130.3 m256.9 m230.1 m785.9 m

Accounts Receivable

679 k5.3 m

Inventories

1.1 m14.7 m

Current Assets

134.3 m258.6 m236.5 m814.8 m

PP&E

440 k1 m2.8 m6.6 m

Total Assets

135.6 m263.9 m255.3 m839.8 m

Accounts Payable

1.9 m6.1 m8 m5.2 m

Current Liabilities

12.4 m24.4 m46.7 m76.8 m

Total Liabilities

228.6 m

Additional Paid-in Capital

302.6 m474.6 m688.8 m1.6 b

Retained Earnings

(179.5 m)(350.5 m)(601.9 m)(990.7 m)

Total Equity

123.2 m124.1 m86.9 m611.2 m

Financial Leverage

1.1 x2.1 x2.9 x1.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

151.1 m295.9 m399.1 m354.4 m302.5 m314.5 m320.2 m647.3 m672.2 m

Accounts Receivable

1.1 m1.1 m510 k3.2 m6.1 m

Inventories

476 k6 m8.4 m12.2 m15.6 m

Current Assets

154.1 m297.7 m401.3 m357.2 m308.5 m325.7 m337.8 m670.1 m707.6 m

PP&E

1.1 m1.1 m1.1 m2.2 m2.6 m2.7 m2.7 m3.8 m8.6 m

Total Assets

156.1 m303.3 m406.5 m363.4 m314.9 m344 m355.9 m689.6 m761 m

Accounts Payable

2.8 m4.1 m5.7 m9.6 m5.6 m12.3 m14 m3.3 m10.3 m

Current Liabilities

19 m21.8 m26.9 m36 m42.7 m58.9 m60 m57.8 m107.5 m

Additional Paid-in Capital

403.5 m470.7 m661.1 m667.3 m676.1 m853.7 m922 m1.4 b1.6 b

Retained Earnings

(266.3 m)(302.6 m)(399 m)(459.6 m)(526.2 m)(692.7 m)(752.6 m)(853.7 m)(1.1 b)

Total Equity

137.1 m168.1 m262.1 m207.7 m149.9 m161 m169.3 m502.2 m513.2 m

Financial Leverage

1.1 x1.8 x1.6 x1.7 x2.1 x2.1 x2.1 x1.4 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.4 m)(171 m)(251.4 m)(387.5 m)

Depreciation and Amortization

179 k349 k1 m3.1 m

Accounts Receivable

(679 k)5.3 m

Inventories

(1.1 m)14.7 m

Accounts Payable

(1.3 m)4.2 m1.9 m5.2 m

Cash From Operating Activities

(84.9 m)(117.5 m)(194.5 m)(287.7 m)

Purchases of PP&E

(400 k)(1 m)(2.3 m)(2.9 m)

Cash From Investing Activities

(2.3 m)(25.9 m)(19.8 m)(23.3 m)

Cash From Financing Activities

92.1 m269.9 m187.6 m866.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(37.1 m)(36.2 m)(48.5 m)(60.6 m)(66.6 m)(90.8 m)(58.4 m)(101.2 m)(136.7 m)

Accounts Receivable

1.1 m1.1 m510 k3.2 m6.1 m

Inventories

476 k6 m8.4 m12.2 m15.6 m

Accounts Payable

2.8 m4.1 m5.7 m9.6 m5.6 m12.3 m14 m3.3 m10.3 m
USDY, 2017

Revenue/Employee

6.9 k

Financial Leverage

1.5 x

TESARO Operating Metrics

FY, 2016

Products

2

Countries

7

Patent Portfolios

3

TESARO Market Value History

TESARO Online and Social Media Presence

TESARO News and Updates

TESARO Company Life and Culture

You may also be interested in